CEO, Candel Therapeutics
A native of Guatemala, Aguilar-Cordova has been a leader in immune-oncology and cancer research for over 20 years in academia and in the biotech field. He has served as principal or co-investigator in more than 25 clinical trials, was the deputy director of the Harvard Gene Therapy Initiative at Harvard Medical School and has served on many oversight committees for the National Institute of Health, the FDA and the World Health Organization. In 2002, Aguilar-Cordova founded Candel Therapeutics, a growing biotechnology firm headquartered in Needham looking for cures for cancer. The firm, which has raised over $50 million in funding in the past few years, develops proprietary immuno-oncology treatments to improve outcomes for cancer patients.